Stabilised sulforaphane for pharmaceutical development
In a significant breakthrough, sulforaphane has been successfully stabilised in a powdered pharmaceutical formulation, extending shelf life from days to years in open air and at ambient temperature.
Evgen holds the rights to a suite of patent applications (compositional and manufacturing methods) to this novel technology: a sulforaphane complex called Sulforadex™. Sulforadex™ has been demonstrated to be orally bioavailable, is biologically active, and has attractive cost of goods, making it an affordable prophylactic for long term use in the reduction of risk of certain cancers.
Pioneering patented state-of-the-art pathway engineering for glucosinolates
Encouraged by the ambitious and successful project of developing a yeast to produce the antimalarial drug artemisinin from a pathway consisting of over 10 genes, the insertion of plant biosynthetic pathways into microorganisms to produce high value products has gained increased interest.
In association with the University of Copenhagen, Evgen is pioneering patented state-of-the-art pathway engineering, by introducing 14 essential genes into a yeast strain, to manufacture Glucoraphanin (the natural precursor to sulforaphane); one of the most promising phytochemicals for the treatment and prevention of a number of human diseases.